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Abstract 
The governance of data used for biomedical research and clinical 
trials is an important requirement for generating accurate results. 
To improve the visibility of data quality and analysis, we 
developed TrialChain, a blockchain-based platform that can be 
used to validate data integrity from large, biomedical research 
studies. We implemented a private blockchain using the 
MultiChain platform and integrated it with a data science platform 
deployed within a large research center. An administrative web 
application was built with Python to manage the platform, which 
was built with a microservice architecture using Docker. The 
TrialChain platform was integrated during data acquisition into 
our existing data science platform. Using NiFi, data were hashed 
and logged within the local blockchain infrastructure. To provide 
public validation, the local blockchain state was periodically 
synchronized to the public Ethereum network. The use of a 
combined private/public blockchain platform allows for both 
public validation of results while maintaining additional security 
and lower cost for blockchain transactions. Original data and 
modifications due to downstream analysis can be logged within 
TrialChain and data assets or results can be rapidly validated when 
needed using API calls to the platform. The TrialChain platform 
provides a data governance solution to audit the acquisition and 
analysis of biomedical research data. The platform provides 
cryptographic assurance of data authenticity and can also be used 
to document data analysis. 
1. Introduction 
Data integrity and governance are key requirements for any data 
management platform. Within biomedical research and clinical 
trials, assurance of data validity and documentation of analytic 
steps are critical for translating results to high quality clinical care. 
Data manipulation, whether unintentional or due to scientific 
fraud [1-8], can be difficult to identify without a robust 
infrastructure for managing data assets. While improving the 
transparency of data acquisition and analysis requires a 
multifaceted approach [9-16], the use of emerging cryptographic 
technologies, such as blockchain, may reduce the risk of data 
manipulation and boost the confidence in conclusions made by 
the scientific community. 
 Software applications for the management and 
governance of biomedical research data are commercially 
available. However, these laboratory information management 
systems (LIMS) and clinical trial management systems (CTMS) 
are typically complex, internally managed systems that are not 
shared among collaborating investigators or sponsoring 
organizations. Furthermore, because these systems are privately 
managed, they are potentially a weak safeguard against 
misconduct. In addition, because of the complexity and expense 
of these systems, they are used in only a limited number of studies 
[17-20]. Novel approaches are therefore needed to improve the 
robustness and transparency of data governance systems as well 
as expand access to their capabilities.  
 Similar issues with stakeholder trust and data integrity 
have been identified in many industries [21-24]. Blockchain, a 
distributed ledger technology originally developed in 2008 for the 
Bitcoin platform [25], is a potential solution to the problem of 
trust in numerous use cases [26 27]. Several organizations, 
particularly in the financial industry, have started to explore 
whether blockchain technology can be successfully integrated 
into existing software to address the need for a more visible and 
immutable audit log [28]. More recently, the use of blockchain for 
applications outside of currency and financial services has also 
received significant attention. Within healthcare, blockchain has 
been proposed as a possible solution for managing patient and 
provider identity, permissions to healthcare data, and to manage 
participant consent [29-31]. 
 Since 2014, the National Center for Cardiovascular 
Disease (NCCD), China in Beijing, has enrolled over 2 million 
participants as part of the China PEACE Million Persons Project 
(MPP) [32]. As a large, distributed study, our goal was to 
implement a platform that could ensure that data integrity and 
provenance could be verified and provide an audit trail of data 
modifications from the time of collection through analysis. The 
MPP data set includes a vast number of structured and 
unstructured data types, such as survey responses, medical 
records, echocardiogram reports, imaging studies, and genomic 
sequencing. Because of the number and diverse types of data 
elements, a strong data governance strategy, which includes both 
data management policies and technical safeguards, is especially 
important. 
To create a robust data management environment, we 
implemented a blockchain-based platform to track data assets 
obtained for the study. The technical basis of blockchain is that 
each entry to the ledger is added to a growing list of blocks which 
are cryptographically signed with the current timestamp and a 
hash of the previous block. Clients, or miners, can then 
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cryptographically validate each transaction to guarantee that data 
within the ledger has not been subsequently modified. While it is 
possible for actors to intentionally fabricate data at the site of 
capture before sharing or storing it, this approach helps guarantee 
that data cannot be maliciously modified after the fact or in bulk 
to fit a desired outcome, and also provides a shared ledger that can 
be viewed and validated by multiple parties. Here, we present the 
technical implementation of the NCCD Data Science Platform 
(NDSP), which includes a blockchain-based application used to 
maintain a cryptographically-secured ledger of data assets. 
2. Methods 
2.1 Data Platform and Data Acquisition 
The TrialChain application was integrated into the NDSP, a data 
science platform developed to provide data management for the 
Million Persons Project. The NDSP core computing platform 
consists of a Hadoop cluster for distributed data management and 
a high-performance computing (HPC) cluster for primary and 
secondary next-generation sequencing (NGS) analysis. Hadoop 
was deployed to a mixed operating system (OS) environment with 
nodes running either CentOS7 or Ubuntu 14.04 (GPU-enabled 
nodes). Core Hadoop applications including the Hadoop 
Distributed File System (HDFS, v 2.7.3), Yet Another Resource 
Negotiator (YARN, v 2.7.3), Spark (v 1.6.2), Hive (v 1.2.1), and 
Sqoop (v 1.4.6) were deployed following best practices for high-
availability and secured with Kerberos (Figure 1). The Apache 
NiFi software (v 0.4.0) was also deployed to an edge node for data 
ingestion and stream processing. Docker was deployed to all edge 
and worker nodes to support a microservice architecture for 
ancillary and analytic applications. The HPC was integrated with 
Hadoop client services and the SLURM resource manager 
deployed on CentOS7. 
2.2 TrialChain Infrastructure and Libraries 
The TrialChain platform was developed with a microservice 
architecture using Docker (v 18.03.1-ce) and deployed with 
Docker Compose (v 1.21.0), based on the Ubuntu 16.04 base 
Docker image (http://github.com/ComputationalHealth/TrialChain). 
The open source MultiChain platform (v 1.0.2) was used for the 
private blockchain infrastructure. The TrialChain software was 
developed in Python (v 3.6.2) with the Savoir (v 1.0.6), Web3.py 
(v 3.16.5), Ethereum (v 2.3.1), and gevent (v 1.2.2) libraries. The 
Falcon (v 1.4.1) and Flask (v 0.12.2) frameworks were used for 
the application programming interface (API) and administrative 
web interface, respectively. The MultiChain Explorer (v 0.8) 
package was used to provide a user interface for introspecting the 
private blockchain. A Docker container running Geth (v 1.8.0), 
the Go implementation of the Ethereum protocol, was also 
deployed to allow for a local cache and link to the public 
Ethereum network. 
3. Results 
3.1 Private Blockchain Architecture 
MultiChain, a private blockchain, was chosen to log data collected 
within the platform, as it offers several advantages over public 
blockchains, as described in detail in the discussion. One such 
advantage is the ability to approve nodes that join the network and 
apply specific permissions to these nodes. As such, the private 
blockchain network is initiated by an initial administrative 
“master” node that creates the new blockchain, defines the chain’s 
parameters, and grants permissions to additional “client” nodes. 
MultiChain can expose a remote procedure call (RPC) endpoint 
that can be used to interact with the network and the master node 
was configured to allow RPC connections from other TrialChain 
components within a shared Docker network (Figure 2A). 
MultiChain client nodes were deployed to create a distributed, 
multi-host architecture. A client node was created for each 
TrialChain component, including the TrialChain web service and 
web portal, and were configured to accept RPC connections from 
the associated TrialChain component on a local Docker network. 
These nodes were then given connect, send, and receive 
permissions from the initial master/administrative node and 
allowed to join the network. This allows for each application to 
run independently and replicates the blockchain data to each host 
to protect from data loss in the event of node failure. All 
transactions, including adding or removing nodes or changing 
node permissions, are logged within the blockchain. 
3.2 Private-Public Blockchain Integration 
While the private blockchain cryptographically links each 
transaction within the MultiChain environment, private 
blockchains have potential limitations related to data immutability. 
To provide additional cryptographic assurance and public 
validation of the private blockchain data, we integrated a public 
blockchain by periodically submitting the state of the private 
chain (latest blockhash) as a transaction on the public Ethereum 
network (Figure 2B). To achieve this private-public integration, 
we deployed a local Ethereum node to synchronize and allow for 
programmatic interaction with the public blockchain. To provide 
an interface to manage the private blockchain and the public 
blockchain integration, we implemented an administrative web 
portal. 
 
 
Figure 1: The NCCD Data Science Platform includes several core 
components from Hadoop for data storage, ingestion, and analysis. 
Other core infrastructure components, such as Apache Zookeeper and 
Ambari, are also used to support the platform. A high-performance 
cluster and GPU-enabled nodes for data analysis were integrated into 
the platform through installation of the Hadoop client applications. 
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Figure 2: TrialChain workflow and integration with the public Ethereum network. A) A master node is initially deployed to create the blockchain and 
assign initial permissions. Subsequently, additional client nodes can be added to the network either locally or, with proper permissions and network 
access, at remote locations. TrialChain services are deployed within individual Docker containers along with MutliChain client nodes to provide local 
access and data replication. B) The TrialChain administrative portal periodically synchronizes the most recent blockhash, which represents the current 
chain state, with the public Ethereum network. 
The backend of the web portal was developed to handle 
constructing and submitting raw transactions to the Ethererum 
network. An Ethereum wallet was created specifically for the 
application, and its private key was exposed to the web portal 
backend through the environment variables of the Docker 
container. Although no Ether is moved in the validation 
transactions, the transaction still carries a small cost to incentivize 
miners on the public network to include it in the proof-of-work, 
so a small but non-zero quantity of Ether must be maintained in 
the administrative account’s wallet. 
The web portal defaults to using the local Ethereum node to 
submit transactions to the network, but if the local chaindata is not 
in-sync, transactions may also be directed through public third-
party APIs such as Infura or BlockCypher. Transactions may be 
scheduled, or an admin user of the web portal can manually 
initiate a validation transaction on the Ethereum network at any 
time and can specify a different external API to use through a 
webform. A dashboard displays the status of the local chaindata 
as well as the dollar-equivalent balance of ether remaining in the 
wallet and the current estimated cost of a validation transaction on 
the Ethereum network.  
When the private-public validation task is initiated, the web 
app backend establishes a connection with the private blockchain 
and retrieves the latest confirmed blockhash. A connection is then 
established with the public Ethereum network through either the 
provided external URL or the local Geth node’s exposed JSON-
RPC API port. A transaction containing the local blockhash and 
any additional metadata is then constructed and signed with the 
local private key (Figure 3A). The transaction costs are estimated 
before submitting the transaction and if the account balance is too 
low, a connection cannot be established, or the transaction request 
does not return a transaction hash response, the user is notified, 
and the transaction is canceled. If the transaction submission is 
successful, the web app records the current time, the submitted 
blockhash, the transaction hash, and the account address of the 
wallet in a local postgres database supporting the web application.  
3.3 TrialChain and NDSP Integration 
To capture data assets entering the NDSP, a REST-based API 
based on the Falcon library was created to provide a secure 
method that could be used to submit data to TrialChain from 
multiple applications or data sources. Data assets can be submitted 
to this API with a valid POST request originating from any 
authorized IP address. Since a majority of data ingestion for this 
platform was performed with the Apache NiFi software, we 
created a custom NiFi workflow to hash and submit the data assets 
to the TrialChain platform. New data assets acquired from a 
number of data sources, including a HPC used for genetic data 
analysis, are retrieved with NiFi and both an md5 and SHA256 
hash are generated. The md5 hash is used as the index ID for the 
MultiChain Asset class when it is issued, as this index is limited 
to 32 characters. The SHA256 hash is recorded as an attribute of 
the data asset to provide further assurance of the data asset, since 
the md5 hashing algorithm is not considered cryptographically 
secure. NiFi is used to add additional metadata to a JSON message 
which is then sent as a POST request to the TrialChain API 
(Figure 3B). The API then submits the necessary data asset 
information to a local MultiChain node and the data is broadcasted 
to the entire network. 
3.4 Retrospective Data Validation 
To determine whether a data asset has been verified in the 
blockchain, along with the initial time of validation, an interface 
to query and review the status of assets on the blockchain was 
added to the administrative web portal. This allows users to verify 
that data existed in a specific state at the specified time, to  
demonstrate that data have not been changed since acquisition. 
When a user submits an md5 hash entered in a webform, the 
application queries the local MultiChain node to identify the asset 
ID that matches the md5 hash. If none is found, the user is notified; 
otherwise, the web application determines at what time the local 
blockchain was subsequently synchronized with the public 
Ethereum network and confirms the status of that transaction. The 
returned metadata includes the transaction receipt, the number of 
confirmations and a hyperlink to the transaction report on the 
etherscan.io website, a publicly available portal for browsing 
Ethereum transactions. An embedded object on the dashboard of 
the web application also exposes the MultiChain explorer so that 
local MultiChain transactions can also be viewed. The same 
functionality was also implemented as a local Python application 
to allow data assets to be hashed locally and verified through an 
API call to the web portal. After generating an md5 and SHA256 
hash for the provided file, the same information provided in the 
web portal is returned as a JSON message to the client and 
displayed to the user through the command line interface (Figure 
3C). 
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Figure 3: TrialChain data models for web service integration. A) The TrialChain administrative portal creates a transaction containing the required 
Ethereum parameters along with the ‘data’ field, which contains the most recent local blockhash. The transaction is signed with the local private key 
and submitted to the network. B) Data assets are hashed within NiFi and a JSON message containing the file hashes, a timestamp, unique source 
identifier, and any additional metadata is submitted to the TrialChain web service to create a local transaction. C) After submitting the hash of a file 
that is already present in the blockchain, TrialChain returns a JSON response with related transaction identifiers, synchronization status with the 
Ethereum network, and related timestamps. 
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Figure 4: TrialChain architecture and workflow. After acquiring data assets, the file hashes are submitted to the TrialChain platform and files are 
stored within the NDSP. Assets are created within the local blockchain and periodically synchronized to the public Ethereum network. Users can 
verify the status of the network and file authenticity through the administrative portal and remote clients can be configured to allow for further data 
distribution. 
4. Discussion 
Through the use of a distributed, cryptographic ledger, the 
TrialChain platform (Figure 4) is able to provide a publicly-
verifiable audit trail of data assets. With the continued growth and 
importance of digital data for clinical trials and other biomedical 
research, novel approaches such as demonstrated here will allow 
for greater confidence in the authenticity of the data used to 
generate results. In addition, the integration of private and public 
blockchain networks offers an approach that can be used to 
decrease the cost of running blockchain-based solutions, while 
still offering a high-level of transparency and authenticity. 
Like Bitcoin and many other major blockchain 
implementations, MultiChain consists of a network of nodes that 
validate shared transaction histories through a proof-of-work 
algorithm [33]. In contrast to public blockchains, only client 
nodes that are expressly known to the master node are permitted 
to participate in mining or to access the chain data. There are 
several advantages to using a private blockchain platform such as 
MultiChain. The software required to run MultiChain, including 
the private blockchain itself, can be locked to a specific version 
of the MultiChain protocol and therefore does not necessarily 
require upgrades to its supporting components as would be 
required to keep pace with development efforts in public 
blockchains. Also, transaction costs can be set when configuring 
the blockchain, and can therefore be free of any monetary or 
cryptocurrency charge besides the cost of maintaining the 
computing resources and, because transactions on the network are 
exclusively for data governance of PEACE and MPP data assets, 
the resources required for rapid transaction uptake and block 
validation is achievable with standard commercial desktops and 
small virtual machines. Furthermore, as the blockchain and any 
metadata associated with the data assets are never disseminated 
outside of the private network, the use of a private chain provides 
an environment to log more sensitive data than would be 
appropriate to be shared on a public network.  
While private blockchains have many advantages, 
because of the small size of the network as well as the lack of 
diversity of incentives among participating nodes, private 
blockchains are vulnerable to mutability through collusion among 
the nodes to either roll back the chain to an earlier state or exclude 
certain transactions from inclusion in a block. Although 
technically difficult, it would be both theoretically possible and 
practically feasible to alter the data verified by this chain after it 
was initially submitted [33 34]. To guarantee that the private chain 
is trustworthy, the latest blockhash in the private chain is 
periodically (once per day) shared with the Ethereum network as 
a transaction on the public ledger. As it is practically infeasible to 
corrupt the public network, it is possible for all stakeholders to 
verify that every data asset in the private chain has been 
unchanged since the nearest synchronization date since its upload. 
For the NDSP, both master and client nodes are running 
within a single institution, however the platform architecture can 
just as easily support nodes installed on external networks, such 
as in systems held by third-party stakeholders. Including 
additional stakeholders with differing incentives as nodes in the 
network therefore provides a concrete mechanism to build trust 
among collaborators while simultaneously making misconduct by 
individual stakeholders more difficult. The distribution of nodes 
also allows stakeholders to maintain a local copy of the 
transaction log for future review or analysis. 
 Since the TrialChain API can accept a web service 
request from multiple sources, hashes can be submitted not only 
at the time of data ingestion, but also for subsequent analyses or 
modification. For example, hashes can be submitted and assets 
created for genomic data pre- and post-alignment, with the latter 
referencing the first asset within the private blockchain. This 
approach allows not only for assurance of data authenticity, but 
also an audit trail of analyses and modifications. The dynamic 
metadata model also allows for assets to contain an evolving set 
of information throughout the course of a study. 
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Given the high value of biomedical data and need for 
verifiability of data assets in clinical trials, blockchain technology 
provides a reasonable solution that can be rapidly integrated into 
existing infrastructure to provide a publicly-verifiable audit log. 
As the number and size of data assets continues to increase, the 
risk of data manipulation, either intentional or accidental, can be 
mitigated with technology safeguards, such as blockchain. In 
particular, the longitudinal aspect of blockchain provides a robust 
and automated layer of protection against retrospective or batch 
data manipulation intended to validate a given hypothesis. While 
not a solution to all potential causes of data manipulation, such as 
fabrication of data at the time and place of capture, implementing 
these technological safeguards can provide rapid assurance to 
study sponsors and the public that data are being used 
appropriately to drive discovery. 
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